
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
UCB | Brussels | EUR | Real-time | |
UCBb | BATS Europe | EUR | Delayed | |
UCBJY | OTC Markets | USD | Delayed | |
0NZT | London | EUR | Real-time | |
UCB | TradeGate | EUR | Delayed | |
UCB | Frankfurt | EUR | Delayed | |
UCB | Vienna | EUR | Real-time |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet/Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops doxecitine/doxribtimine for TK2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; UCB0222 for the treatment of Parkinson’s disease; and UCB9741 and UCB1381 for atopic dermatitis. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Jonathan M. Peacock | 67 | 2021 | Independent Chair of the Board |
Georges Jacobs de Hagen | 85 | 2005 | Honorary Chairman |
Diégo du Monceau de Bergendal | 75 | 1984 | Honorary Chairman |
Prince Lorenz | - | 2001 | Honorary Director |
Jean-Louis Vanherweghem | - | - | Honorary Director |
Peter J. Fellner | 82 | 2005 | Honorary Director |
Alan John Blinken | - | - | Honorary Director |
Thomas Fulton Wilson McKillop | 82 | 2009 | Honorary Director |
Gerhard N. Mayr | 79 | 2005 | Honorary Chairman |
Daniel Janssen | 89 | - | Honorary Deputy Chairman |
Jean-Pierre Kinet | 72 | 2008 | Honorary Director |
Guy Keutgen | - | 1990 | Honorary Director |
Mark Eyskens | - | 2005 | Honorary Chairman |
Karel Boone | 82 | 2000 | Honorary Chairman |
Norman J. Ornstein | 77 | 2008 | Honorary Director |
Frederic Roch Doliveux | 69 | 2005 | Honorary Director |
Arnoud de Pret Roose de Calesberg | 81 | 2005 | Honorary Director |
Jonkheer Cédric van Rijckevorsel | 55 | 2014 | Director |
Alice Dautry | 75 | 2015 | Honorary Director |
Charles-Antoine Emmanuel T. Janssen | 54 | 2012 | Vice-Chair of the Board |
Jean van Rijckevorsel | - | 1992 | Honorary Director |
Ulf Arne Wiinberg | 67 | 2016 | Independent Director |
Jean-Christophe Tellier | 66 | 2014 | CEO & Executive Director |
Cyril Janssen | 54 | 2015 | Director |
Jan Berger | 68 | 2019 | Independent Director |
Susan Gasser | 70 | 2021 | Independent Director |
Maelys Castella | 59 | 2023 | Independent Director |
Rodolfo J. Savitzky | 63 | 2024 | Independent Director |
Dolca Thomas | 55 | 2024 | Independent Director |
Dame Kay Davies | 74 | 2014 | Independent Director |
Gaëtan van de Werve | - | 2006 | Honorary Director |
Albrecht De Graeve | 70 | 2010 | Honorary Director |
Nefertiti Greene | 54 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review